Erratum: A Novel Semisynthetic Inhibitor of the FRB Domain of Mammalian Target of Rapamycin Blocks Proliferation and Triggers Apoptosis in Chemoresistant Prostate Cancer Cells (Mol Pharmacol (2013) 83 (531-541) DOI: 10.1124/mol.112.081349);A novel semisynthetic inhibitor of the FRB domain of mammalian target of rapamycin blocks proliferation and triggers apoptosis in chemoresistant prostate cancer cells

Molecular Pharmacology

Volumn 83, Issue 2, 2013, Pages 531-541

  Morad, Samy A F ^a,b   Schmid, Maximilian ^a   Büchele, Berthold ^a   Siehl, Hans Ullrich ^a   Gafaary, Menna El ^a   Lunov, Oleg ^a   Syrovets, Tatiana ^a   Simmet, Thomas ^a  

^a UNIVERSITY OF ULM   (Germany)

^b South Valley University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

3 CINNAMOYL 11 KETO BETA BOSWELLIC ACID; CYCLIN D1; DECTIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 4E; LIVER KINASE B1 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; PROTEIN P70; S6 KINASE; TERPENOID DERIVATIVE; TUBERIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CHORIOALLANTOIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG SYNTHESIS; EMBRYO; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 84872710532     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.081349err     Document Type: Erratum

References (43)

1. Alao JP, Gamble SC, Stavropoulou AV, Pomeranz KM, Lam EW, Coombes RC, and Vigushin DM (2006) The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. Mol Cancer 5:7.
2. Antonarakis ES, Carducci MA, and Eisenberger MA (2010) Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 291:1-13.
3. Bai X and Jiang Y (2010) Key factors in mTOR regulation. Cell Mol Life Sci 67: 239-253.
4. Belsner K, Büchele B, Werz U, Syrovets T, and Simmet T (2003) Structural analysis of pentacyclic triterpenes from the gum resin of Boswellia serrata by NMR spec-troscopy. Magn Reson Chem 41:115-122.
5. Bianchini A, Loiarro M, Bielli P, Busà R, Paronetto MP, Loreni F, Geremia R, and Sette C (2008) Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis 29: 2279-2288.
6. Brown RE, Zotalis G, Zhang PL, and Zhao B (2008) Morphoproteomic confirmation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer. Int J Clin Exp Pathol 1:333-342.
7. Büchele B and Simmet T (2003) Analysis of 12 different pentacyclic triterpenic acids from frankincense in human plasma by high-performance liquid chromatography and photodiode array detection. J Chromatogr B Analyt Technol Biomed Life Sci 795:355-362.
8. Carroll AG, Voeller HJ, Sugars L, and Gelmann EP (1993) p53 oncoene mutations in three human prostate cancer cell lines. Prostate 23:123-134.
9. Chen Y, Zheng Y, and Foster DA (2003) Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 22:3937-3942.
10. Cuaz-Pérolin C, Billiet L, Baugé E, Copin C, Scott-Algara D, Genze F, Büchele B, Syrovets T, Simmet T, and Rouis M (2008) Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-β-boswellic acid in LPS-challenged ApoE-/-mice. Arterioscler Thromb Vasc Biol 28:272-277.
11. De P, Baltas M, and Bedos-Belval F (2011) Cinnamic acid derivatives as anticancer agents - a review. Curr Med Chem 18:1672-1703.
12. Efeyan A and Sabatini DM (2010) mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 22:169-176.
13. Estrada AC, Syrovets T, Pitterle K, Lunov O, Büchele B, Schimana-Pfeifer J, Schmidt T, Morad SA, and Simmet T (2010) Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells. Mol Pharmacol 77:378-387.
14. Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, and Gaboury LA et al. (2010) eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci USA 107:14134-14139.
15. Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM, Parsons SH, Brail LH, Colligan BM, and Koop JW et al. (2009) eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 69:3866-3873.
16. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H, and Sabatini DM (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15: 148-159.
17. Guo L, Mishra G, Taylor K, and Wang X (2011) Phosphatidic acid binds and stimulates Arabidopsis sphingosine kinases. J Biol Chem 286:13336-13345.
18. Hanlon AD, Larkin MI, and Reddick RM (2010) Free-solution, label-free proteinprotein interactions characterized by dynamic light scattering. Biophys J 98: 297-304.
19. Hay N and Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18: 1926-1945.
20. Hollander MC, Blumenthal GM, and Dennis PA (2011) PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 11: 289-301.
21. Jiang BH and Liu LZ (2008) Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 11:63-76.
22. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA, and Nagle RB (2006) Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66:1203-1212.
23. Leone M, Crowell KJ, Chen J, Jung D, Chiang GG, Sareth S, Abraham RT, and Pellecchia M (2006) The FRB domain of mTOR: NMR solution structure and inhibitor design. Biochemistry 45:10294-10302.
24. Lunov O, Syrovets T, Büchele B, Jiang X, Röcker C, Tron K, Nienhaus GU, Walther P, Mailänder V, and Landfester K et al. (2010) The effect of carboxydextran-coated superparamagnetic iron oxide nanoparticles on c-Jun N-terminal kinase-mediated apoptosis in human macrophages. Biomaterials 31:5063-5071.
25. Neises B and Steglich W (1978) 4-Dialkylaminopyridines as acylation catalysts. 5. Simple method for esterification of carboxylic-acids. Angew Chem Int Ed Engl 17: 522-524.
26. Park B, Prasad S, Yadav V, Sung B, and Aggarwal BB (2011) Boswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets. PLoS ONE 6:e26943.
27. Röcker C, Pötzl M, Zhang F, Parak WJ, and Nienhaus GU (2009) A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles. Nat Nanotechnol 4:577-580.
28. Rohde J, Heitman J, and Cardenas ME (2001) The TOR kinases link nutrient sensing to cell growth. J Biol Chem 276:9583-9586.
29. Scheper GC, van Kollenburg B, Hu J, Luo Y, Goss DJ, and Proud CG (2002) Phos-phorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA. J Biol Chem 277:3303-3309.
30. Shen Z, Wen XF, Lan F, Shen ZZ, and Shao ZM (2002) The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin Cancer Res 8: 2085-2090.
31. Stacey DW (2003) Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 15:158-163.
32. Syrovets T, Büchele B, Krauss C, Laumonnier Y, and Simmet T (2005a) Acetylboswellic acids inhibit lipopolysaccharide-mediated TNF - a induction in monocytes by direct interaction with IkappaB kinases. J Immunol 174:498-506.
33. Syrovets T, Gschwend JE, Büchele B, Laumonnier Y, Zugmaier W, Genze F, and Simmet T (2005b) Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. J Biol Chem 280:6170-6180.
34. Thomsen R and Christensen MH (2006) MolDock: a new technique for high-accuracy molecular docking. J Med Chem 49:3315-3321.
35. Toschi A, Lee E, Xu L, Garcia A, Gadir N, and Foster DA (2009) Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol 29:1411-1420.
36. Veverka V, Crabbe T, Bird I, Lennie G, Muskett FW, Taylor RJ, and Carr MD (2008) Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene 27: 585-595.
37. Wang H, Syrovets T, Kess D, Büchele B, Hainzl H, Lunov O, Weiss JM, Scharffetter-Kochanek K, and Simmet T (2009) Targeting NF-k B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis. J Immunol 183: 4755-4763.
38. Wang X, Yue P, Chan CB, Ye K, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Fu H, Khuri FR, and Sun SY (2007) Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol 27:7405-7413.
39. Yadav VR, Prasad S, Sung B, Gelovani JG, Guha S, Krishnan S, and Aggarwal BB (2012) Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers. Int J Cancer 130:2176-2184.
40. Yoon MS, Sun Y, Arauz E, Jiang Y, and Chen J (2011) Phosphatidic acid activates mammalian target of rapamycin complex 1 (mTORC1) kinase by displacing FK506 binding protein 38 (FKBP38) and exerting an allosteric effect. J Biol Chem 286: 29568-29574.
41. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, and Kwiatkowski DJ (2007) PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 117:730-738.
42. Zhao H, Dupont J, Yakar S, Karas M, and LeRoith D (2004) PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 23:786-794.
43. Zoncu R, Efeyan A, and Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12:21-35.